Zimmer Biomet to Acquire Embody, For Up To $275M

Zimmer Biomet Holdings (NYSE and SIX: ZBH), a Warsaw, IN-based medical expertise firm, acquired Embody, a Norfolk, VA-based privately-held medical gadget firm targeted on smooth tissue therapeutic.

The value of the transaction – topic to customary closing situations and anticipated to be accomplished in February 2023 – was $155 million at closing and up to an extra $120 million topic to attaining future regulatory and industrial milestones over a 3 12 months interval. The acquisition is predicted to be accretive to total income progress and barely dilutive to adjusted earnings per share in 2023.

Led by CEO Jeff Conroy, Embody gives a platform with novel collagen-based bio-fabrication methods and merchandise for the sports activities drugs market. Its merchandise deal with the restore of great tendon and ligament accidents and are developed in shut collaboration with medical thought leaders.

The acquisition consists of Embody’s full portfolio of collagen-based biointegrative options to help therapeutic in probably the most difficult orthopedic smooth tissue accidents – together with the TAPESTRY® biointegrative implant for tendon therapeutic and TAPESTRY® RC, an arthroscopic implant system for rotator cuff restore.

Led by Bryan Hanson, Chairman, President and CEO. Zimmer Biomet is a medical expertise firm with a complete portfolio designed to maximize mobility and enhance well being. The firm transforms the affected person expertise by means of merchandise and suite of built-in digital and robotic applied sciences that leverage knowledge, knowledge analytics and synthetic intelligence.



Leave a Comment